Lonza signs agreement with Canadian plant extracts
of therapeutic plant extracts and bioactive molecules, announced
that it has signed a product development and licensing agreement
with Lonza Inc., the US subsidiary of Swiss chemicals company Lonza
Group Ltd.
Canadian life science company, Fytokem Products Inc., a developer of therapeutic plant extracts and bioactive molecules, announced that it has signed a product development and licensing agreement with Lonza Inc., the US subsidiary of Swiss chemicals company Lonza Group Ltd. The two companies will collaborate on the development and commercialisation of a variety of natural chemical products and formulations based on plant-based bio active extracts. "The Lonza Group is the second industry leading chemical supplier to partner with us," said Art Hesje, President and Chief Executive Officer of Fytokem. "Plant-based bio-actives are an area of interest for Lonza," commented Allan Kushins, Vice President, Marketing for Lonza Performance Chemicals." We believe the plants from the Canadian prairie offer us an opportunity to develop new active ingredients and Fytokem has a very promising library of botanicals in this area. Their science is impressive, and they have a low-cost commercialisation process which adds to the appeal of their compounds," he added. Fytokem Products Inc. is involved in the commercialisation of novel Function-Certified™ plant-based substances - extracts, phytochemicals and bioactive molecules - for use as ingredients in personal care, nutraceutical, pharmaceutical and bio-industrial products, both domestically and internationally. The company has developed a proprietary commercial scale manufacturing process.
